The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Pfizer is licensing a promising investigational cancer medicine from a smaller company. This move improves the drugmaker's ...

19, Pfizer announced it was entering into a licensing agreement with 3SBio, a China-based biotech ... particularly thanks to its $43 billion acquisition of the smaller cancer specialist Seagen.

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

The license deal grants Pfizer (PFE) an exclusive global license ... as well as an option for commercialization rights in China. 3SBio will receive an upfront payment of $1.25B and is eligible ...

Despite recent underperformance, a "Buy" rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength.

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...

a million-square-foot warehouse proposed on the former Pfizer Pigments site at Wood Avenue and Hackett Avenue. Most of the site rests in Wilson, with some land in the city of Easton and a ...